Bush vetoes NIH funding bill

This morning (November 13), President Bush vetoed a bill aiming to linkurl:increase;http://www.the-scientist.com/news/display/45169/ 2008 NIH funding by $1.4 billon, from $28.6 billion linkurl:in 2007;http://www.the-scientist.com/news/display/49077/ to $30 billion next year. The bill outlined a total of $150.7 billion which includes funding for the departments of Labor and Education. Bush previously threatened to veto the bill, which both houses of Congress linkurl:passed;http://www.the-scientis

By | November 13, 2007

This morning (November 13), President Bush vetoed a bill aiming to linkurl:increase;http://www.the-scientist.com/news/display/45169/ 2008 NIH funding by $1.4 billon, from $28.6 billion linkurl:in 2007;http://www.the-scientist.com/news/display/49077/ to $30 billion next year. The bill outlined a total of $150.7 billion which includes funding for the departments of Labor and Education. Bush previously threatened to veto the bill, which both houses of Congress linkurl:passed;http://www.the-scientist.com/blog/display/53852/ last week, because it spends $9.8 billion more than his proposed budget. According to the linkurl:Associated Press,;http://hosted.ap.org/dynamic/stories/B/BUSH?SITE=MAFIT&SECTION=HOME&TEMPLATE=DEFAULT in remarks released by the White House, Bush railed against the Democrat-controlled Congress, saying that the majority was "acting like a teenager with a new credit card." Despite the support of more than 50 Republicans, Congress failed to pass the bill with the two-thirds majority necessary to override Bush's veto. linkurl:The bill;http://thomas.loc.gov/cgi-bin/bdquery/z?d110:HR03043:@@@R will now be sent back to Capitol Hill for a vote to override the veto.

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech